Ignite Creation Date:
2024-05-06 @ 1:26 AM
Last Modification Date:
2024-10-26 @ 11:04 AM
Study NCT ID:
NCT01806597
Status:
COMPLETED
Last Update Posted:
2018-02-22
First Post:
2013-01-23
Brief Title:
Study of Safety Tolerability and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Moderate to Severe Palmoplantar Psoriasis |
Keywords:
| Name | View |
|---|---|
| Skin condition itching psoriasis vulgaris relapsing remitting psoriasis immune-med systemic disease skin lesions scaly patches papules plaques | View |